Dapagliflozin versus sacubitril –valsartan for heart failure with mildly reduced or preserved ejection fraction
Conclusion:Dapagliflozin provides a better monetary value than sacubitril–valsartan in preventing the composite outcome of total HF hospitalizations and CVD among patients with HFmrEF or HFpEF.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Dapagliflozin | Diovan | Drugs & Pharmacology | Forxiga | Heart | Heart Failure